Perspective: Use of protein S100B as a quality assurance marker for endovascular therapy in acute ischemic stroke

被引：0

作者：

Lieschke, Franziska ^{[1
]}

Foerch, Christian ^{[1
,2
]}

机构：

[1] Goethe Univ Frankfurt, Univ Hosp, Dept Neurol, Frankfurt, Germany

[2] RKH klin Ludwigsburg, Dept Neurol, Ludwigsburg, Germany

来源：

FRONTIERS IN NEUROLOGY | 2025年 / 16卷

关键词：

quality assurance; biomarker; S100B; acute ischemic stroke; mechanical thrombectomy; SURROGATE MARKER; BRAIN-DAMAGE; SERUM S100B; THROMBECTOMY; RETRIEVER; RELEASE;

D O I：

10.3389/fneur.2025.1488018

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Mechanical thrombectomy (MT) is a highly effective treatment for ischemic stroke associated with large vessel occlusion. Given its complexity, this procedure is widely used throughout the world in hospitals with different levels of experience. Therefore, practical quality assurance is advised to ensure a high standard of care across the board. In this perspective article, we propose the implementation of measuring serum S100B after MT as a surrogate outcome parameter for the extent of tissue damage as an additional quality indicator for internal and external benchmarking in endovascular therapy. We focus on the analysis of patients, in whom there is a discrepancy between the expected (e.g., based on favorable preconditions) and the actual biomarker outcome. We aim to illustrate the advantages and drawbacks of measuring S100B after MT, reliably depicting the procedure's quality and its use for comparison and identification of "outlier" patients in MT patient cohorts for further process and single-case analysis.

引用

页数：5

共 35 条

[1] Jovin T.G., Chamorro A., Cobo E., de Miquel M.A., Molina C.A., Rovira A., Et al., Thrombectomy within 8 hours after symptom onset in ischemic stroke, N Engl J Med, 372, pp. 2296-2306, (2015)
[2] Berkhemer O.A., Fransen P.S.S., Beumer D., van den Berg L.A., Lingsma H.F., Yoo A.J., Et al., A randomized trial of Intraarterial treatment for acute ischemic stroke, N Engl J Med, 372, pp. 11-20, (2014)
[3] Campbell B.C.V., Mitchell P.J., Kleinig T.J., Dewey H.M., Churilov L., Yassi N., Et al., Endovascular therapy for ischemic stroke with perfusion-imaging selection, N Engl J Med, 372, pp. 1009-1018, (2015)
[4] Saver J.L., Goyal M., Bonafe A., Diener H.C., Levy E.I., Pereira V.M., Et al., Stent-retriever Thrombectomy after intravenous t-PA vs. t-PA alone in stroke, N Engl J Med, 372, pp. 2285-2295, (2015)
[5] Saver J.L., Jahan R., Levy E.I., Jovin T.G., Baxter B., Nogueira R.G., Et al., Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial, Lancet, 380, pp. 1241-1249, (2012)
[6] Nogueira R.G., Lutsep H.L., Gupta R., Jovin T.G., Albers G.W., Walker G.A., Et al., Trevo versus merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial, Lancet, 380, pp. 1231-1240, (2012)
[7] Luger S., Koerbel K., Martinez Oeckel A., Schneider H., Maurer C.J., Hintereder G., Et al., Role of S100B serum concentration as a surrogate outcome parameter after mechanical Thrombectomy, Neurol Int, 97, pp. e2185-e2194, (2021)
[8] Rhyne P.W., Wong O.T., Zhang Y.J., Weiner R.S., Electrochemiluminescence in bioanalysis, Bioanalysis, 1, pp. 919-935, (2009)
[9] Herrmann M., Vos P., Wunderlich M.T., de Bruijn C.H., Lamers K.J., Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentrations of protein S-100B and glial fibrillary acidic protein, Stroke, 31, pp. 2670-2677, (2000)
[10] Foerch C., Singer O.C., Neumann-Haefelin T., du Mesnil de Rochemont R., Steinmetz H., Sitzer M., Evaluation of serum S100B as a surrogate marker for long-term outcome and infarct volume in acute middle cerebral artery infarction, Arch Neurol, 62, pp. 1130-1134, (2005)

← 1 2 3 4 →